Danaher Corporation (DHR) to Distribute Quarterly Dividend of $0.40 on October 30th

Danaher Corporation (NYSE:DHR) declared a quarterly dividend on Tuesday, September 15th. Investors of record on Wednesday, September 30th will be given a dividend of 0.40 per share by the conglomerate on Friday, October 30th. This represents a c) annualized dividend and a yield of 0.8%. The ex-dividend date is Wednesday, September 30th.

Danaher has raised its dividend payment by an average of 0.1%per year over the last three years and has increased its dividend every year for the last 2 years. Danaher has a dividend payout ratio of 18.7% meaning its dividend is sufficiently covered by earnings. Equities research analysts expect Danaher to earn $9.26 per share next year, which means the company should continue to be able to cover its $1.60 annual dividend with an expected future payout ratio of 17.3%.

Danaher Stock Performance

Shares of DHR opened at $208.46 on Thursday. The company has a current ratio of 1.65, a quick ratio of 1.25 and a debt-to-equity ratio of 0.48. The firm’s fifty day simple moving average is $203.50 and its two-hundred day simple moving average is $191.90. Danaher has a 12 month low of $160.93 and a 12 month high of $242.80. The stock has a market capitalization of $146.55 billion, a P/E ratio of 37.03, a price-to-earnings-growth ratio of 2.61 and a beta of 0.78.

Danaher (NYSE:DHR) last posted its quarterly earnings data on Monday, July 20th. The conglomerate reported $1.94 earnings per share for the quarter, topping the consensus estimate of $1.85 by $0.09. Danaher had a return on equity of 11.04% and a net margin of 15.95%.The firm had revenue of $6.26 billion during the quarter, compared to analyst estimates of $6.12 billion. During the same period last year, the company posted $0.77 EPS. The business’s quarterly revenue was up 5.5% on a year-over-year basis. As a group, analysts predict that Danaher will post 8.53 EPS for the current year.

About Danaher

Danaher Corporation (NYSE:DHR) is a global science and technology company that develops products, services and solutions for the life sciences, biotechnology and diagnostics markets. Its businesses support pharmaceutical and biotechnology research, biomanufacturing, clinical laboratories and healthcare providers.

The company’s portfolio includes bioprocessing technologies, laboratory instruments, consumables, reagents and software. Key businesses include Cytiva, which provides biomanufacturing solutions; Beckman Coulter, which supplies laboratory diagnostics and automation systems; Leica Biosystems, which develops pathology products; and IDT, which provides genomic and nucleic acid products.